Asia stocks rise: Japan surges on Takaichi bets, China buoyed by positive GDP
Alzamend Neuro, Inc. (NASDAQ:ALZN) filed Certificates of Elimination on Tuesday with the Secretary of State of Delaware to remove its Series B and Series C convertible preferred stock from its Certificate of Incorporation. The filing, effective upon submission, eliminates all provisions related to these preferred stock designations from the company’s charter. The company maintains a strong liquidity position with a current ratio of 6.03, indicating its ability to meet short-term obligations, though InvestingPro data shows the company is rapidly burning through its cash reserves.
According to the company’s statement in a press release, the Certificates of Elimination were filed October 14, 2025, and apply to both the Series B and Series C convertible preferred stock. Copies of the Certificates were included as exhibits in the filing. Trading at $2.24, the stock has experienced significant pressure, down nearly 86% over the past year. InvestingPro analysis suggests the stock is currently undervalued, with 14 additional exclusive insights available to subscribers.
Alzamend Neuro is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol ALZN.
This information is based on a statement from the company’s SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.